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Abstract
Background: Leukocyte Immunoglobulin-like Receptor-1 (LIR-1) and LIR-2 (also known as ILT2
and ILT4 respectively) are highly related cell surface receptors that bind a broad range of class I
MHC molecules with low (M) affinities. Expressed on monocytic cells and macrophages, both
molecules transmit inhibitory signals after binding ligands. In addition to binding host class I MHC,
the LIR-1 molecule, which is also expressed on lymphoid tissues, binds with a high (nM) affinity to
UL18, a class I MHC homolog encoded by Human Cytomegalovirus (HCMV). In comparison, LIR-
2 binds UL18 only weakly (M KD). To understand how HCMV preferentially targets the more
broadly expressed LIR-1 molecule, we determined the crystal structure of a ligand-binding fragment
of LIR-2, and compared this to the existing high-resolution crystal structure of LIR-1.
Results: Recombinant LIR-2 (domains 1 and 2) was produced in E. coli and crystallized using streak
seeding to optimize the crystal morphology. A data set complete to 1.8 Å was collected at 100 K
from a single crystal in the P41212 spacegroup. The structure was solved by molecular replacement,
using a search model based on the LIR-1 structure.
Conclusions: The overall structure of LIR-2 D1D2 resembles both LIR-1, and Killer Inhibitory
Receptors, in that the A strand in each domain forms hydrogen bonds to both  sheets, and there
is a sharp angle between the two immunoglobulin-like domains. However, differences from LIR-1
are observed in each domain, with two key changes apparent in the ligand-binding domain, D1. The
region corresponding to the residue 44–57 helix of LIR-1 adopts a topology distinct from that of
both LIR-1 and the KIR structures, involving a shortened 310 helix. Secondly, the predicted UL18
binding region of LIR-1 is altered substantially in LIR-2: the 76–84 loop mainchain is displaced 11 Å
with respect to LIR-1, and Tyrosine 38 adopts an alternative rotamer conformation. In summary,
the structure of LIR-2 has revealed significant differences to LIR-1, including ones that may help to
explain the >1000-fold lower affinity of LIR-2 for UL18.
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The Leukocyte Immunoglobulin-like Receptor (LIR) fam-
ily (also called the ILT's, MIR's and CD85) comprises a set
of immunoreceptors expressed on the surface of lym-
phoid and myeloid cells [1,2]. Encoded from within the
Leukocyte Receptor Cluster [3] (a region of human chro-
mosome 19 which also encompasses the loci for the relat-
ed Killer Inhibitory Receptor (KIR) and Leukocyte-
Associated Immunoglobulin-like Receptor (LAIR) fami-
lies), the LIRs are highly similar to one another (63–84%
amino acid identity in the extracellular region). All except
LIR-4 (which appears to encode a soluble molecule) en-
code type-1 transmembrane proteins, containing either
two or four immunoglobulin superfamily (IgSF) domains
in their extracellular regions. One subset of cell surface LIR
molecules (LIR-1, -2, -3, -5, and -8) possesses Intracellular
Tyrosine-based Inhibitory Motifs (ITIMs) in the cytoplas-
mic domain. Once phosphorylated, these sequences me-
diate association with intracellular SH2-domain-
containing phosphatases, permitting transmission of in-
hibitory signals to the effector cell. Another group (LIR-6,
-7, ILT7, -8, -11) includes short cytoplasmic domains con-
taining no known signaling motifs. These molecules have
a charged amino acid (arginine) within their transmem-
brane regions, enabling them to transmit activatory sig-
nals by associating with the adaptor molecule FcRI.
The best characterized members of the LIR family are LIR-
1 (ILT-2) and LIR-2 (ILT-4), both of which are inhibitory
receptors with four extracellular IgSF domains, and cyto-
plasmic ITIM motifs mediating association with the phos-
phatase SHP-1 [4–7]. Both LIR-1 and LIR-2 bind to class I
MHC molecules and are expressed on monocytes and
dendritic cells [5]. However, unlike LIR-2, LIR-1 is also ex-
pressed on lymphoid tissues, namely all B-cells, as well as
some T-cells and subsets of NK cells [5]. In vitro experi-
ments in a range of immune effector cells, including
monocytes, macrophages, dendritic cells and (for LIR-1)
B-cells, have shown that upon cross-linking with antibod-
ies, LIR-1 and LIR-2 can each abrogate activatory signals
resulting in a potent inhibition of effector functions [5–
7]. Similarly, engagement of class I MHC ligands by LIR-1
expressed on NK and T-cells has been shown to potently
inhibit cytotoxicity [6,8].
Following the discovery that LIR-1 is the receptor for the
Human Cytomegalovirus (HCMV) class I MHC homolog
UL18 [4], both LIR-1 and LIR-2 were shown to bind a
broad range of endogenous class I MHC molecules [5–
7,9,10], with affinities in the micromolar (M) range [11].
Domain-swapping experiments established that binding
to both UL18 and class I MHC proteins is mediated by in-
teraction between surfaces on the membrane distal (D1)
domain of LIR-1 or LIR-2 and the 3 domain of either
class I MHC or UL18 [11]. Despite the high sequence
identity between LIR-1 and LIR-2 (82% in the extracellular
region), and the similar mode and affinity of their interac-
tions with endogenous class I MHC, the UL18 protein dis-
tinguishes effectively between the two receptors, binding
LIR-1 with a nanomolar (nM) affinity, over 1000-fold
more strongly than it binds to LIR-2 [11]. Recently, a crys-
tal structure of the two membrane-distal domains of LIR-
1 (D1-D2) indicated both similarities to and differences
from the KIR receptor family [11]. A parallel mutagenesis
study resulted in the identification of a group of residues
on LIR-1 domain 1 that were proposed to form part of the
binding site for UL18 [11]. In order to further investigate
the structural features of the LIR family of immunorecep-
tors, and in particular the ability of UL18 to preferentially
target the LIR-1 molecule, we determined the crystal struc-
ture of a ligand-binding fragment of LIR-2.
Results and Discussion
Production, characterization and crystallisation of LIR-2
The N-terminal two domains of LIR-2 (residues 1–197)
were produced in a manner similar to LIR-1, by overex-
pression in E. coli, followed by purification from inclusion
bodies, and renaturation by dilution refolding [11]. Size-
exclusion of refolded material (Figure 1A) indicated a
peak of protein eluting before the 13.7 kDa marker pro-
tein, and subsequent SDS-PAGE analysis (Figure 1B) con-
firmed this contained predominantly one major band
corresponding to the expected molecular weight of the
LIR-2 D1-2 fragment (22 kDa). Under non-reducing con-
ditions, this band migrated as one species of a higher mo-
bility (Figure 1B), suggesting a single combination of
disulphide bonds was formed during refolding. Peak frac-
tions from the size-exclusion purification were collected,
concentrated, and used directly for crystallization experi-
ments. Initial trials yielded microcrystals, and following
optimization of the conditions, streak seeding was used to
grow single crystals of a size (approximately 0.16 mm 
0.16 mm  0.05 mm) sufficient for data collection.
Crystal structure of LIR-2
The crystal structure of LIR-2 D1D2 was determined in the
space group P41212 to 1.8 Å by molecular replacement us-
ing the LIR-1 D1D2 structure [12]. Overall, the structure
closely resembles that of LIR-1 in that it consists of two Ig-
like domains related by an approximately orthogonal an-
gle, forming a highly bent structure (Figure 2A). As with
LIR-1, each domain is composed primarily of  strands ar-
ranged into two antiparallel sheets, with a KIR-like folding
topology, whereby the first strand of each domain forms
hydrogen bonds to both the B and G strands, thereby
bridging the two  sheets [12].
The structure of LIR-1 D1D2 revealed helical regions inter-
spersed with  structure in each of the two domains [12].
In particular, the region of each domain corresponding toPage 2 of 9
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Purification and characterization of soluble LIR-2 D1D2. A: Size exclusion chromatography of refolded LIR-2 D1D2.
Refolded LIR-2 D1D2 elutes from a Superdex 200 column at just before a 13.7 kDa marker protein, consistent with the pro-
tein behaving as a compact monomer in solution. The elution volumes of 232, 67 and 13.7 kDa standard proteins are indicated.
B: SDS-PAGE analysis of refolded LIR-2. Identical samples of size-exclusion purified LIR-2 D1D2 (~5 g) were loaded onto a
15% acrylamide SDS gel, under either reducing (R) or non-reducing (NR) conditions. The molecular weights of marker pro-
teins (M) are shown in kilodaltons. Under reducing conditions, LIR-2 migrates in a position consistent with its predicted molec-
ular weight of 22 kDa. Under non-reducing conditions, LIR-2 D1D2 migrates as a single band of higher mobility, suggesting
formation of the appropriate disulfide bonds. No higher molecular weight cross-linked species are observed.
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feature that was not observed in the related KIR and Fc-re-
ceptor families or other IgSF domains. In each domain,
LIR-2 contains significantly less helical structure than LIR-
1 in this C' strand region. In D1, a single helical turn dis-
playing a 310 hydrogen bonding pattern is observed over
residues 52–55, whereas the preceding region (residues
48–50) adopts a -strand conformation as observed in
KIR receptors [13–15]. In contrast, this entire region of
LIR-1 D1 (residues 44–57) adopts a helical conformation,
interrupted only by a proline at position 51 [12]. This
change in topology is accompanied by a significant shift
in the LIR-2 main chain relative to LIR-1 D1 over residues
48–50, a conformation stabilized by main chain hydro-
gen bonding with the C strand. Such an arrangement,
with retention of the C' strand followed by a single turn of
310 helix, is similar to that observed in LIR-1 D2 [12].
In the region corresponding to the C' strand of D2, topo-
logical differences from LIR-1 are also observed. The sin-
gle turn of 310 helix observed in LIR-1 (residues 148–150)
is absent in LIR-2. Instead, this and the adjacent D strand
(151–153) are replaced by a region incorporating a hy-
drogen bonded turn. As a result of these rearrangements,
the two structures differ substantially over residues 146–
154 (equivalent to 147–155 in LIR-1), with a maximum
Figure 2
LIR-2 D1D2 Crystal structure. A: Ribbon diagram of the structure LIR-2 D1D2 and comparison with the LIR-1 D1D2
structure. Dashed lines indicate disordered loops. Arrows indicate the single turn of 310 helix observed in LIR-2 D1 (residues
52–55), in comparison to the longer 310 helical segment (residues 44–57) in the same region of LIR-1 D1. 410 and 310 helices
are shown in red, Polyproline II helices in green. The root mean square deviation between the two structures is 3.05 Å for
domain 1 and 2.31 Å for D2 for all carbon alpha atoms. B: Conformational change in D2 146–154 loop relative to LIR-1. The
LIR-2 loop is shown in ball-and-stick representation. The LIR-1 loop is shown in blue as a ribbon diagram. The conformational
difference is maximal at residue Ala 150 (equivalent to Ala 151 in LIR-1), where the C positions differ by 14 Å. C: Crystal
contacts involving the D2 146–154 loop for LIR-2 and LIR-1 (147–155). Both LIR-1 (left panel) and LIR-2 (right panel) are
shown in cyan with the loop region highlighted in red, and the equivalent neighboring molecule shown in grey.
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1), where the C positions are shifted by ~14 Å (Figure
2B). The turn region is stabilized by two internal hydro-
gen bonds (between the carbonyl oxygen of His 149 and
the main chain nitrogen of Gly 152; also between the side
chain hydroxyl of Ser 153 and the carbonyl oxygen of Arg
155) and by four main chain hydrogen bonds to residues
connecting the D2 B and C strands (Ser 123, Phe 127, Gly
128, Phe 130). This conformational change between the
structures is unexpected as the two proteins are identical
in sequence over this region, and most probably reflects
the substantially different packing in the LIR-1 and LIR-2
crystals (Figure 2C). In the LIR-2 crystals, the 146–154
turn appears relatively unconstrained, packing loosely
against the D1 domain of a neighboring molecule, and
forming a single  3.6 Å contact from Pro 148 to Gln 27.
In contrast, the analogous neighboring molecule is orient-
ed differently in the LIR-1 structure, packing more closely,
and forming direct contacts to the 147–155 region from
both the D1 and D2 domains (Figure 2C). Furthermore,
an additional D2-D2 crystal contact specific to the LIR-2
crystal appears to be incompatible with the LIR-1 confor-
mation.
In contrast with these changes, regions of polyproline II
helix observed in the F-G loop regions of LIR-1 are pre-
served in both LIR-2 domains. These left-handed helices
are characterized by a three residue repeat and phi, psi an-
gles near -75, 145 [16], and include the sequences
WSELS (D1) and WSSPS (D2), both variations of the
WSXWS sequence motif of haematopoietic receptors [17].
In each case, main chain nitrogen and side chain serine
hydroxyls in positions n and n + 3 form hydrogen bonds
to the main chain of the F strand, a feature also observed
for cytokine receptors [18–21], KIRs [13–15] and fi-
bronectin III repeats [22].
LIR-2 interdomain interface
LIR-2 maintains a similar interdomain angle to LIR-1
(88% versus 90% for LIR-1 in the same space group), con-
sistent with conservation of the majority (8/13) of the in-
terdomain contact residues. However, superimposition of
the D1 domains of LIR-1 and LIR-2 reveals a slight lateral
shift in the orientation of D2, such that residues at the tip
of D2 distal to the interdomain interface are shifted by ap-
proximately 5 Å. The most significant amino acid change
at the LIR-2 interface involves the introduction of a larger
Met residue for Val at residue 94 (equivalent to residue 95
in LIR-1). This causes a reorientation of Trp 67 and an ac-
companying shift in the main chain of 2 Å at this position.
The Ala to Thr alteration at residue 70 appears to stabilize
this shift, by introducing a hydrogen bond between the
Thr hydroxyl group and the carbonyl oxygen of Trp 67.
Conformational differences from LIR-1 in the UL18-bind-
ing region of domain 1
A mutagenesis study of LIR-1 identified residues in the
membrane-distal tip of the A'CC'FG face of D1 as impor-
tant for UL18-binding [12]. This region (Figure 3A) is dis-
tant from the D1D2 elbow region that KIRs use to contact
class I MHC molecules [13,23]. Mutation of LIR-1 Tyr 38
to Ala reduced UL18 binding affinity by ~18-fold, and a
triple mutant (Y76A/D80A/R84A) showed a similar (~20-
fold) reduction in affinity [12]. The analogous residues in
LIR-2 (Tyr 38, Gln 76, Arg 80 and Trp 83) either exhibit an
altered conformation, a different side chain, or both. Al-
though Tyr 38 is conserved in both structures, the
sidechain positions differ: in LIR-1, Tyr 38 is a solvent-ex-
posed residue on the C strand, which points towards the
D1 RSESS motif connecting the F and G strands and is
within hydrogen-bonding distance of the hydroxyl oxy-
gen of Ser 87 (Figure 3B). In LIR-2 the residue equivalent
to Ser 87 is a leucine, and as a result Tyr 38 reorients such
that it points towards the N-terminus of the C strand with
its hydroxyl group within hydrogen-bonding distance of
the amino group of Gln 76 (Figure 3C). The other residues
implicated in LIR-1 binding to UL18 (equivalent to LIR-2
residues 76, 80, and 83) are located in the F to G turn (res-
idues 76–84). In LIR-2, this region contains a one residue
deletion relative to LIR-1, and two glycine to non-glycine
changes (G78 and G83, corresponding to Y78 and R82 in
LIR-2), and undergoes a significant conformational shift
relative to LIR-1. Whereas this region protrudes from the
A'CC'FG face of D1 in LIR-1, in LIR-2 it is oriented closer
to residues 28–32 connecting the B and C strands (Figure
3D). In each case the conformation is stabilized by three
main chain hydrogen bonds within the turn region, and
for LIR-2 the shift is accompanied by an additional hydro-
gen bond between the carbonyl oxygen of Tyr 78 and the
main chain NH group of Gln 33. The conformational shift
in this region culminates at residue 80, where the C po-
sitions are greater than 11 Å apart (Figure 3D).
In LIR-1, the region identified as the UL18 binding site is
involved in crystal contacts to a symmetry-related mole-
cule [12]. Similarly, the 76–84 loop of LIR-2 is involved in
crystal contacts to another D1D2 protein, although in LIR-
2 contacts are made to residues on the F and G strands of
the D2 domain of a neighbouring molecule, whereas in
LIR-1 they are to the same UL18-binding surface on the
D1 domain of the neighbouring molecule. Nevertheless,
the fact that in each structure this region of the molecule
is involved in crystal contacts, and the relatively large total
surface area involved (810–870 Å2 for LIR-1 and 877 Å2
for LIR-2 compared to an average of 570 Å2 for non-spe-
cific crystal contacts [24]) may reflect the fact that this sur-
face is well-suited to protein-protein interactions and is
therefore used for both ligand binding and crystal pack-
ing.Page 5 of 9
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The structure of LIR-2 D1D2 reported here closely resem-
bles that of the highly related LIR family member, LIR-1.
Both proteins are composed of two IgSF domains related
by a nearly orthogonal angle to create a highly bent struc-
ture. The folding topologies of the two LIR-2 domains
closely resemble their LIR-1 counterparts, although a re-
duction in helical content is observed in the LIR-2 do-
mains. The D1-D2 interdomain angle is comparable to
that of LIR-1 D1D2, in both cases being maintained by a
set of conserved hydrophobic interactions at the interdo-
main interface.
Despite these similarities, the HCMV class I MHC ho-
molog UL18 binds LIR-1 with an ~2 nM affinity, whereas
UL18 binds LIR-2 with an ~14 M affinity [12]. Further-
more, whereas a LIR-1 Fc fusion protein bound to cell sur-
face UL18, no binding was observed between cell surface
UL18 and a LIR-2 Fc fusion protein [25]. The structure of
LIR-2 D1D2 reveals changes from LIR-1 in both domains,
some of which could potentially provide a molecular ba-
Figure 3
Alteration of the UL18-binding site in LIR-2 D1. A. Structure of LIR-2 D1. The region of LIR-2 analogous to the pro-
posed UL18-binding site in LIR-1. Main chain regions of the 76–84 F-G loop and Tyr 38, both of which implicated in LIR-1/UL18
interaction, are indicated in red. Side chains for LIR-2 residues 38 (Tyr), 76 (Gln), 80 (Arg) and 86 (Leu) are also shown. B.
Conformation of Tyr 38 in LIR-1. Likely hydrogen bonds in (B) and (C) are shown as dotted lines. C. Conformation of Tyr 38
in LIR-2. The Ser (87) to Leu (86) change would cause a steric clash with the LIR-1 conformation of Tyr 38, and forces a side
chain reorientation towards Gln 76. In LIR-1, substitution of Gln 76 for Tyr would similarly prevent adoption of the LIR-2 Tyr
38 orientation due to steric hindrance. D. Conformational shift of the 76–84 loop region. The LIR-1 loop (dark blue) protrudes
from the side of the domain
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changes involves a conformational difference in the re-
gion of D2 residues 146–154, but the sequence of this re-
gion is conserved between LIR-1 and LIR-2 [25], and the
conformational change appears to be mediated by differ-
ent intermolecular contacts in the LIR-1 and LIR-2 crys-
tals. Consequently, while the two conformations
observed may well indicate this region of the receptors
displays a degree of flexibility in solution, it is unlikely to
explain discrimination between LIR-1 and LIR-2 by UL18.
In contrast, changes in D1 are more likely to significantly
affect binding to UL18, since previous experiments sug-
gest that D1 is the main site of interaction with UL18 (and
class I MHC) [11]. Likely to be especially relevant are
those changes observed in the predicted UL18-binding
site, namely the reorientation of Tyr 38 and the 11 Å con-
formational change in the 76–84 region of the D1 F to G
loop. Mutation of Tyr 38 to Ala reduced LIR-1/UL18 bind-
ing by ~18 fold [12]. In LIR-1, the hydroxyl oxygen of Tyr
38 is oriented towards the RSESS motif connecting the F
and G strands, and hydrogen bonds to Ser 87. However,
in LIR-2 a Ser to Leu change at this position forces a reori-
entation of the Tyr 38 side chain (Figure 3B), towards the
N-terminus of the C strand, a conformation stabilized by
hydrogen bonding to the amino group of Gln 76.
Another potentially important alteration in the UL18-
binding site is a conformational change in the 76–84 F-G
loop, mutation of which reduced UL18 binding by LIR-1
by ~20 fold [12]. One notable feature of the LIR-1 and
LIR-2 structures is that in each case the 76–84 loop is in-
volved in crystal contacts, and thus the structure in the
crystal could represent only one of many conformations
occupied in solution. Nevertheless, the changes observed
in this region evident in the LIR-1 and LIR-2 crystal struc-
tures may well reflect energetic preferences for distinct
loop conformations. It is notable that the LIR-1 loop is
one residue longer and contains two glycine residues ab-
Table 1: Data Collection and Refinement Statistics for LIR-2 D1D2
Space Group P41212
Unit Cell Dimensions (Å) 62.505, 62.505, 106.845
Data Collection
Resolution (Å) 34.1–1.8 (2.0–1.8)
Number of Observed Reflections 155116
Number of Independent Reflections 20290
aCompleteness (%) 99.35 (100)
bRmerge (%) 4.0 (33.0)
I/ (I) 43.4 (5.9)
Refinement
Resolution (Å) 54.2–1.8
Reflections in working set 19241 (1405)
Reflections in test set 991, equivalent to 4.9%
cRcryst (%) 23. 23.4
dRfree> (%) 27.3
Number of atoms
Protein 1559
184 of 198 residues
Water 161
Average B factor 33.87 Å2
Anisotropic B correction
B11 = B22 = 0.37 Å2, B33 = -0.74 Å2
Model Geometry
Rms deviation from ideality Bond lengths
Bond lengths (Å) 0.021
Bond angles (deg) 1.858
Ramachandran plot quality
Most favoured Region of Ramachandran plot (%) 91.90%
Additionally allowed Protein 8.10%
Generously allowed 0.0%
Disallowed 0.0%
aCompleteness = (number of independent reflections/total theoretical number) bRmerge (I) = (|I(i) - <I(h)>|/I(i)), where I(i) is the ith observation 
of the intensity of the hkl reflection and <I> is the mean intensity from multiple measurements of the h,k,l reflection. cRcryst (F) = h||Fobs(h)| - 
|Fcalc(h)||/h|Fobs(h)| and |Fcalc(h)| are the observed and calculated structure factor amplitudes for the h, k, l reflection. dRfree is calculated over 
reflections in a test set not included in atomic refinement. Figures in parentheses apply to data in the highest resolution shell.Page 7 of 9
(page number not for citation purposes)
BMC Structural Biology 2002, 2 http://www.biomedcentral.com/1472-6807/2/6sent in the LIR-2 sequence, and therefore the LIR-2 loop
may be considerably restricted in conformation relative to
LIR-1. While amino acid differences in this loop could in
themselves be sufficient to reduce UL18 binding, the main
chain conformation adopted by LIR-2 might preclude for-
mation of favorable contacts between this region and
UL18, thereby contributing to a lower affinity for the viral
ligand. In contrast, both receptors bind class I MHC pro-
teins with similar (M) affinities, and it may be that ener-
getically significant contacts with this region are enhanced
in the UL18-LIR-1 interaction relative to class I MHC in-
teractions with either LIR-1 or LIR-2, where they may be
either minimal or absent. Crystal structures of either re-
ceptor in complex with UL18 or class I MHC should help
resolve some of these issues.
Materials and Methods
Protein expression
PCR was used to amplify the sequence encoding domains
1 and 2 of LIR-2 (residues 1–198 of the mature protein)
from cDNA kindly provided by David Cosman. LIR-2
D1D2 was expressed in E. coli from the pET23a vector, pu-
rified from inclusion bodies essentially as described [26],
and solubilized in 8 M Guanidine Hydrochloride, 50 mM
Tris pH 8.0. Solubilized protein was renatured by dilution
into a standard refolding buffer (400 mM L-Arginine, 100
mM Tris, 10 mM EDTA, 0.5 mM reduced Gluathione, 5
mM oxidized Glutathione, pH 8.3). The final concentra-
tion of protein was approximately 50 g/ml. Renatured
protein was concentrated, then purified by size exclusion
chromatography using a Pharmacia Superdex 200 col-
umn, into 150 mM NaCl, 20 mM Tris pH 8.0). Purifed
protein was concentrated and quantified by absorption
measurements at 280 nm. An extinction coefficient (280
nm) for LIR-2 of 46785 M-1cm-1 was calculated using the
method of Pace et al[27].
Crystallization, data collection and processing
All crystals were grown at 23C. Initial microcrystals of
LIR-2 were obtained by vapor diffusion in 1:1 l hanging
drops of 6.1 mg/ml protein equilibrated with a reservoir
solution of 0.1 M Hepes pH 7.5, 10% Isopropanol, 20%
PEG 4 K. Crystals of a quality sufficient for data collection
were obtained by streak seeding from existing crystals into
5:5 l sitting drops of 1.9 mg/ml protein equilibrated
overnight with 50 mM MES pH 6.5, 5% Isopropanol, 10%
PEG 4000, using a chinchilla whisker. A 1.8 Å native data
set was collected at 100 K from a single crystal using a
Quantum CCD Reseach Detector at the Stanford Synchro-
tron Radiation Laboratory beamline 9–2 (	 = 0.999 Å).
The crystal was soaked in cryoprotectant solutions consist-
ing of mother liquor incorporating 8.5%, 17% (10 min-
utes each), and then 25% Ethylene Glycol (30 minutes),
prior to immersion in liquid nitrogen. Diffraction due to
ice formation was reduced significantly by the use of flash
annealing [28]. Data were processed and scaled using
DENZO and SCALEPACK [29].
Structure solution, refinement and analysis
The structure of LIR-2 D1D2 was solved by molecular re-
placement using AmoRe [30]. A rotation and translation
function was found using the 1.8 Å LIR-2 data set and the
2.1 Å structure of LIR-1 D1D2 as the search model (corre-
lation coefficient 35%, R factor 49%). Rigid body refine-
ment (20–4 Å) resulted in an Rcryst of 47% and an Rfree of
49%. Solvent flattened maps calculated to 2.5 Å were used
for initial rebuilding. Anisotropy and bulk solvent correc-
tions were applied and the model partially refined using
individual temperature (B) factors with CNS [31] (Rcryst =
31%, Rfree = 32 %), after which cycles of real space and re-
ciprocal space refinement were carried out, followed by
addition of water molecules in the final stages of refine-
ment. Residues at the N terminus of the fragment (1–2)
and within two loops (42–46 and 136–141) are not seen
in the electron density and were omitted from the model,
and side chains for residues 3, 11, 47, 51, 56, 57 and 166
and 167 are disordered and were truncated to alanines.
Disulphide bonds are observed between residues 26 and
75, 121 and 173, and 133 and 143. For analysis of inter-
domain angles, contacts and buried surface areas, D1 was
defined as residues 1–97 and D2 was defined as residues
98–197, as for LIR-1 [12]. Interdomain contact residues
were identified using the program CONTACT [32], and
defined as residues containing an atom within 3.6 Å of the
partner domain. Buried surface areas were calculated us-
ing SURFACE [32] with a 1.4 Å probe radius. Interdomain
angles were calculated using the program Dom_angle
[33], which determines the angle between the long axes of
adjacent domains that are approximated by ellipsoids cal-
culated from the coordinates. Figures 2 and 3 were pre-
pared with Molscript [34] and Raster3D [35].
Authors' contributions
BEW expressed, purified and produced high quality crys-
tals of LIR-2, carried out data collection and processing,
structure solution, refinement and analysis and also wrote
the manuscript. LMT carried out the latter stages of refine-
ment and aided structural analyses. TLC produced initial
microcrystals of LIR-2. APH carried out molecular cloning
of the LIR-2 expression construct. APW provided help dur-
ing data collection and processing, and critical scientific
discussions. PJB conceived of the study, participated in its
design and coordination, and provided financial support.
Acknowledgements
We thank Drs Z.A. Hamburger, C. A. O'Callaghan and W.L. Martin for as-
sistance with crystallographic software and valuable scientific discussions; 
D. Cosman for LIR-2 cDNA; S. Rowland-Jones for the kind gift of chinchilla 
whiskers; and members of the Bjorkman laboratory for critical reading of 
the manuscript. BEW is supported by a Wellcome Trust Traveling Fellow-
ship (Grant code GR059939MF). Requests for coordinates should be ad-
dressed to BEW.Page 8 of 9
(page number not for citation purposes)
BMC Structural Biology 2002, 2 http://www.biomedcentral.com/1472-6807/2/6References
1. Cella M, Nakajima H, Facchetti F, Hoffmann T, Colonna M: ILT re-
ceptors at the interface between lymphoid and myeloid
cells. Curr Top Microbiol Immunol 2000, 251:161-6
2. Borges L, Cosman D: LIRs/ILTs/MIRs, inhibitory and stimulato-
ry Ig-superfamily receptors expressed in myeloid and lym-
phoid cells. Cytokine Growth Factor Rev 2000, 11:209-17
3. Wende H, Colonna M, Ziegler A, Volz A: Organization of the leu-
kocyte receptor cluster (LRC) on human chromosome
19q13.4. Mamm Genome 1999, 10:154-60
4. Cosman D, Fanger N, Borges L, Kubin M, Chin W, Peterson L, Hsu
ML: A novel immunoglobulin superfamily receptor for cellu-
lar and viral MHC class I molecules. Immunity 1997, 7:273-82
5. Fanger NA, Cosman D, Peterson L, Braddy SC, Maliszewski CR, Borg-
es L: The MHC class I binding proteins LIR-1 and LIR-2 inhibit
Fc receptor-mediated signaling in monocytes. Eur J Immunol
1998, 28:3423-34
6. Colonna M, Navarro F, Bellon T, Llano M, Garcia P, Samaridis J, Ang-
man L, Cella M, Lopez Botet M: A common inhibitory receptor
for major histocompatibility complex class I molecules on
human lymphoid and myelomonocytic cells [see com-
ments]. J Exp Med 1997, 186:1809-18
7. Colonna M, Samaridis J, Cella M, Angman L, Allen RL, O'Callaghan
CA, Dunbar R, Ogg GS, Cerundolo V, Rolink A: Human myelo-
monocytic cells express an inhibitory receptor for classical
and nonclassical MHC class I molecules. J Immunol 1998,
160:3096-100
8. Vitale M, Castriconi R, Parolini S, Pende D, Hsu ML, Moretta L, Cos-
man D, Moretta A: The leukocyte Ig-like receptor (LIR)-1 for
the cytomegalovirus UL18 protein displays a broad specifici-
ty for different HLA class I alleles: analysis of LIR-1 + NK cell
clones. Int Immunol 1999, 11:29-35
9. Navarro F, Llano M, Bellon T, Colonna M, Geraghty DE, Lopez-Botet
M: The ILT2(LIR1) and CD94/NKG2A NK cell receptors re-
spectively recognize HLA-G1 and HLA-E molecules co-ex-
pressed on target cells. Eur J Immunol 1999, 29:277-83
10. Allan DS, Colonna M, Lanier LL, Churakova TD, Abrams JS, Ellis SA,
McMichael AJ, Braud VM: Tetrameric complexes of human his-
tocompatibility leukocyte antigen (HLA)-G bind to periph-
eral blood myelomonocytic cells. J Exp Med 1999, 189:1149-56
11. Chapman TL, Heikema AP, Bjorkman PJ: The inhibitory receptor
LIR-1 uses a common binding interaction to recognize class
I MHC molecules and the viral MHC homolog UL18. Immunity
1999, 11:603-11
12. Chapman TL, Heikema AP, West AP Jr, Bjorkman PJ: Crystal struc-
ture and ligand binding properties of the D1D2 region of the
inhibitory receptor LIR-1 (ILT2). Immunity 2000, 13:727-36
13. Fan QR, Long EO, Wiley DC: Crystal structure of the human
natural killer cell inhibitory receptor KIR2DL1-HLA-Cw4
complex. Nat Immunol 2001, 2:452-60
14. Maenaka K, Juji T, Stuart DI, Jones EY: Crystal structure of the hu-
man p58 killer cell inhibitory receptor (KIR2DL3) specific for
HLA-Cw3-related MHC class I. Structure Fold Des 1999, 7:391-8
15. Snyder GA, Brooks AG, Sun PD: Crystal structure of the HLA-
Cw3 allotype-specific killer cell inhibitory receptor
KIR2DL2. Proc Natl Acad Sci U S A 1999, 96:3864-9
16. Adzhubei AA, Sternberg MJ: Left-handed polyproline II helices
commonly occur in globular proteins. J Mol Biol 1993, 229:472-
93
17. Bazan JF: Structural design and molecular evolution of a cy-
tokine receptor superfamily. Proc Natl Acad Sci U S A 1990,
87:6934-8
18. de Vos AM, Ultsch M, Kossiakoff AA: Human growth hormone
and extracellular domain of its receptor: crystal structure of
the complex. Science 1992, 255:306-12
19. Somers W, Ultsch M, De Vos AM, Kossiakoff AA: The X-ray struc-
ture of a growth hormone-prolactin receptor complex. Na-
ture 1994, 372:478-81
20. Livnah O, Stura EA, Johnson DL, Middleton SA, Mulcahy LS, Wrighton
NC, Dower WJ, Jolliffe LK, Wilson IA: Functional mimicry of a
protein hormone by a peptide agonist: the EPO receptor
complex at 2.8 A. Science 1996, 273:464-71
21. Bravo J, Staunton D, Heath JK, Jones EY: Crystal structure of a cy-
tokine-binding region of gp130. Embo J 1998, 17:1665-74
22. Huber AH, Wang YM, Bieber AJ, Bjorkman PJ: Crystal structure of
tandem type III fibronectin domains from Drosophila neuro-
glian at 2.0 A. Neuron 1994, 12:717-31
23. Boyington JC, Motyka SA, Schuck P, Brooks AG, Sun PD: Crystal
structure of an NK cell immunoglobulin-like receptor in
complex with its class I MHC ligand. Nature 2000, 405:537-43
24. Janin J: Specific versus non-specific contacts in protein crys-
tals. Nat Struct Biol 1997, 4:973-4
25. Borges L, Hsu ML, Fanger N, Kubin M, Cosman D: A family of hu-
man lymphoid and myeloid Ig-like receptors, some of which
bind to MHC class I molecules. J Immunol 1997, 159:5192-6
26. Willcox BE, Gao GF, Wyer JR, O'Callaghan CA, Boulter JM, Jones EY,
van der Merwe PA, Bell JI, Jakobsen BK: Production of soluble al-
phabeta T-cell receptor heterodimers suitable for biophysi-
cal analysis of ligand binding. Protein Sci 1999, 8:2418-23
27. Pace CN, Vajdos F, Fee L, Grimsley G, Gray T: How to measure
and predict the molar absorption coefficient of a protein. Pro-
tein Sci 1995, 4:2411-23
28. Yeh JI, Hol WG: A flash-annealing technique to improve dif-
fraction limits and lower mosaicity in crystals of glycerol ki-
nase. Acta Crystallogr D Biol Crystallogr 1998, 54:479-80
29. Otwinowski Z, Minor W: Processing of X-ray diffraction data
collected in oscillation mode. Methods Enzymol 1997, 276:307-26
30. Navaza J: AMORE – an automated package for molecular re-
placement. Acta Crystallogr 1994, A 50:157-63
31. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-
Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS, et al: Crys-
tallography & NMR system: A new software suite for macro-
molecular structure determination. Acta Crystallogr D Biol
Crystallogr 1998, 54:905-21
32. CCP4: The CCP4 suite: programs for protein crystallogra-
phy. Acta Crystallogr 1994, D 50:760-3
33. Su XD, Gastinel LN, Vaughn DE, Faye I, Poon P, Bjorkman PJ: Crystal
structure of hemolin: a horseshoe shape with implications
for homophilic adhesion. Science 1998, 281:991-5
34. Kraulis PJ: MOLSCRIPT: a program to produce both detailed
and schematic plots of protein structures. J Appl Crystallogr
1991, 24:946-50
35. Merritt EA, Murphy MEP: Raster3D Version 2.0, a program for
photorealistic molecular graphics. Acta Crystallogr 1994, D
50:869-73
Publish with BioMed Central  and  every 
scientist can read your work free of charge
"BioMedcentral will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Paul Nurse, Director-General, Imperial Cancer Research Fund
Publish with BMC and your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours - you keep the copyright
editorial@biomedcentral.com
Submit your manuscript here:
http://www.biomedcentral.com/manuscript/
BioMedcentral.comPage 9 of 9
(page number not for citation purposes)
